KMDA News and Press, Kamada Ltd.

REHOVOT, Israel, and HOBOKEN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced ...

Riskified Ltd. Class A (RSKD) is expected to report $0.02 for Q4 2025 SunOpta Inc. (STKL) is expected to report $0.05 for Q4 2025 One Liberty Properties Inc. (OLP) is expected to report $0.41 for Q4 2025 Tourmaline Oil Corp (TRMLF) is expected to report $0.35 for Q4 2025 StubHub H...

By Meg Flippin Benzinga DETROIT, MICHIGAN - January 13, 2026 ( NEWMEDIAWIRE ) - Kamada Ltd. (NASDAQ: KMDA), a global biopharmaceutical company and provider of specialty plasma-derived products, is confident it is heading into 2026 in a position of significant strength, with continued double-d...

2026-01-08 09:34:20 ET Thesis Read the full article on Seeking Alpha For further details see: Kamada 2025/2026 Outlook: Evaluating Revenue Growth And Product Drivers

2026-01-07 11:49:38 ET More on Kamada Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript Kamada Ltd. (KMDA) Q3 2025 Earnings Call Transcript Kamada GAAP EPS of $0.09 in-line, revenue of $47M misses by $...

2026 Guidance Represents Year-Over-Year Increase of 13% in Revenues and 23% in Adjusted EBITDA Based on Mid-Point of 2025 Annual Guidance 2026 Annual Guidance is Based Solely on Continued Organic Growth Company Continues to Focus on Securing New Business Development and M&A T ransa...

Company Awarded Extension to Existing Supply Tender Relating to its Portfolio of Four Specialty Plasma-Derived Products Supply Extension Secures Ongoing Sales of Approximately $5.0-$7.0 Million Per Year for the Period Between Q2-26 and Q1-28 Kamada Reiterates its 2025 Full-Year Revenue Guid...

2025-12-09 06:15:06 ET H.C. Wainwright analyst issues BUY recommendation for KMDA on December 9, 2025 11:11AM ET. The previous analyst recommendation was Buy. KMDA was trading at $6.73 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...

2025-12-08 09:26:49 ET Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook December 8, 2025 8:30 AM EST... Read the full article on Seeking Alpha For further details see: Kamada Ltd. (KMDA) Discusses Discontinuation of Pha...

Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint K amada Continues to Supply GLASSIA®, its AAT-IV Treatment, Marketed Internationally Including in the U.S. and ...